Circle Pharma and Pfizer have entered an agreement to develop a screening library of macrocyclic peptides.

According to the agreement, Circle Pharma will be responsible to provide computational design and synthetic chemistry platform and develop physical screening of specific macrocyclic peptides.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With non-exclusive rights to the screen library against specific targets, Pfizer will support the development of the library.

The agreement enables the two partners to develop a library that will contain hundreds of macrocycles to derive disease processes and create derivative libraries designed specifically for a therapeutic target class.

Multiple Myeloma Research Foundation (MMRF) and Memorial Sloan Kettering Cancer Centre (MSKCC) have entered a co-development agreement to advance the clinical trials on multiple myeloma and develop precision medicine for myeloma patients.

See Also:

The agreement enables the partners to launch new clinical trials for multiple myeloma, further develop patient’s genetic fingerprints of the disease during diagnosis, and define myeloma subclones during therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"With non-exclusive rights to screen library against specific targets, Pfizer will support the development of the library."

Pharmaceutical manufacturer and distributor Sinchuan Languang Development plans to issue bonds due 2021.

The company expects to raise up to $448.5m from the offering.

Agios Pharmaceuticals plans to raise gross proceeds of up to $150m through the public offering of shares of its common stock.

J.P.Morgan Securities and Goldman, Sachs & Co are acting as book running managers, while Wilmer Cutler Pickering Hale and Dorr is acting as legal adviser for the offering.

The company plans to invest the funds to increase the working capital and for general corporate purposes.

Image: Circle Pharma and Pfizer have entered an agreement to develop screening library of macrocyclic peptides. Photo: courtesy of Neruru via Wikipedia.